Racial differences in neuromyelitis optica spectrum disorder

被引:132
|
作者
Kim, Su-Hyun [1 ]
Mealy, Maureen A. [3 ]
Levy, Michael [3 ]
Schmidt, Felix [4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Ruprecht, Klemens [5 ]
Paul, Friedemann [4 ,5 ,6 ,7 ,8 ,9 ,10 ]
Ringelstein, Marius [11 ]
Aktas, Orhan [11 ]
Hartung, Hans-Peter [11 ]
Asgari, Nasrin [12 ,13 ]
Tsz-Ching, Jessica Li [14 ]
Siritho, Sasitorn [15 ]
Prayoonwiwat, Naraporn [15 ]
Shin, Hyun-June [1 ]
Hyun, Jae-Won [1 ]
Han, Mira [2 ]
Leite, Maria Isabel [16 ]
Palace, Jacqueline [16 ]
Kim, Ho Jin [1 ]
机构
[1] Natl Canc Ctr, Res Inst & Hosp, Dept Neurol, Goyang, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Biometr Res Branch, Goyang, South Korea
[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[4] Charite Univ Med Berlin, NeuroCure Clin Res Ctr, Berlin, Germany
[5] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany
[6] Free Univ Berlin, Berlin, Germany
[7] Humboldt Univ, Berlin, Germany
[8] Berlin Inst Hlth, Berlin, Germany
[9] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, Berlin, Germany
[10] Charite Univ Med Berlin, Berlin, Germany
[11] Heinrich Heine Univ, Dept Neurol, Med Fac, Dusseldorf, Germany
[12] Univ Southern Denmark, Dept Neurol, Slagelse Hosp, Odense, Denmark
[13] Univ Southern Denmark, Inst Reg Hlth Res & Mol Med, Odense, Denmark
[14] Queen Elizabeth Hosp, Dept Neurol, Hong Kong, Peoples R China
[15] Mahidol Univ, Siriraj Hosp, Dept Med, Bangkok, Thailand
[16] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England
关键词
CLINICAL CHARACTERISTICS; MULTICENTER; AQUAPORIN-4; FEATURES; COHORT; EPIDEMIOLOGY; ASSOCIATION; ANTIBODIES; MYELITIS; NMO;
D O I
10.1212/WNL.0000000000006574
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective We aimed to evaluate racial differences in the clinical features of neuromyelitis optica spectrum disorder. Methods This retrospective review included 603 patients (304 Asian, 207 Caucasian, and 92 Afro-American/Afro-European), who were seropositive for anti-aquaporin-4 antibody, from 6 centers in Denmark, Germany, South Korea, United Kingdom, United States, and Thailand. Results Median disease duration at last follow-up was 8 years (range 0.3-38.4 years). Asian and Afro-American/Afro-European patients had a younger onset age than Caucasian patients (mean 36, 33, and 44 years, respectively; p < 0.001). During the disease course, Caucasian patients (23%) had a lower incidence of brain/brainstem involvement than Asian (42%) and Afro-American/Afro-European patients (38%) (p < 0.001). Severe attacks (visual acuity <= 0.1 in at least one eye or Expanded Disability Status Scale score >= 6.0 at nadir) at onset occurred more frequently in Afro-American/Afro-European (58%) than in Asian (46%) and Caucasian (38%) patients (p = 0.005). In the multivariable analysis, older age at onset, higher number of attacks before and after immunosuppressive treatment, but not race, were independent predictors of severe motor disabilities at last follow-up. Conclusion A review of a large international cohort revealed that race affected the clinical phenotype, age at onset, and severity of attacks, but the overall outcome was most dependent on early and effective immunosuppressive treatment.
引用
收藏
页码:E2089 / E2099
页数:11
相关论文
共 50 条
  • [21] Pregnancy outcomes in neuromyelitis optica spectrum disorder
    Vishnevetsky, A.
    Levy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 140 - 140
  • [22] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [23] Cyclophosphamide treatment in Neuromyelitis Optica Spectrum Disorder
    Gulluoglu, H.
    Uysal, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 798 - 798
  • [24] Urinalysis in patients with neuromyelitis optica spectrum disorder
    Chen, Z. G.
    Huang, J.
    Fan, R.
    Weng, R. H.
    Shinohara, R. T.
    Landis, J. R.
    Chen, Y.
    Jiang, Y.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (04) : 619 - 625
  • [25] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [26] A new era for neuromyelitis optica spectrum disorder
    Silbermann, Elizabeth
    Bourdette, Dennis
    LANCET, 2019, 394 (10206): : 1304 - 1305
  • [27] Neuromyelitis Optica Spectrum Disorder Presented with Pseudoathetosis
    Seok, Hung Youl
    Eun, Mi-Yeon
    Jang, Seong Hwa
    You, Sooyeoun
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 419 - 419
  • [28] Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
    Simon Fung
    Matt Shirley
    CNS Drugs, 2023, 37 : 363 - 370
  • [29] Hemifacial anhidrosis in neuromyelitis optica spectrum disorder
    Miyaue, Noriyuki
    Yabe, Hayato
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2020, 8 (02): : 107 - 108
  • [30] Choroid Plexitis in Neuromyelitis Optica Spectrum Disorder
    Oh, Y. J.
    Lim, Y. M.
    Lee, E. J.
    Kim, H. J.
    Kim, K. K.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) : 380 - 381